HUP0401154A2 - NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására - Google Patents

NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására

Info

Publication number
HUP0401154A2
HUP0401154A2 HU0401154A HUP0401154A HUP0401154A2 HU P0401154 A2 HUP0401154 A2 HU P0401154A2 HU 0401154 A HU0401154 A HU 0401154A HU P0401154 A HUP0401154 A HU P0401154A HU P0401154 A2 HUP0401154 A2 HU P0401154A2
Authority
HU
Hungary
Prior art keywords
horses
cats
dogs
receptor antagonists
unwanted behavior
Prior art date
Application number
HU0401154A
Other languages
English (en)
Hungarian (hu)
Inventor
Brian Scott Bronk
Mary Anne Hickman
Carolyn Rose Kilroy
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0401154A2 publication Critical patent/HUP0401154A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/49Cinchonan derivatives, e.g. quinine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0401154A 2001-07-20 2002-07-15 NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására HUP0401154A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30669201P 2001-07-20 2001-07-20
PCT/IB2002/002847 WO2003009848A1 (en) 2001-07-20 2002-07-15 Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses

Publications (1)

Publication Number Publication Date
HUP0401154A2 true HUP0401154A2 (hu) 2004-10-28

Family

ID=23186426

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401154A HUP0401154A2 (hu) 2001-07-20 2002-07-15 NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására

Country Status (13)

Country Link
US (1) US20030139443A1 (enExample)
EP (1) EP1411946A1 (enExample)
JP (1) JP2005504029A (enExample)
KR (1) KR20040029375A (enExample)
CN (1) CN1529600A (enExample)
CA (1) CA2448722A1 (enExample)
CZ (1) CZ200434A3 (enExample)
HU (1) HUP0401154A2 (enExample)
IL (1) IL158990A0 (enExample)
PL (1) PL367944A1 (enExample)
SK (1) SK252004A3 (enExample)
WO (1) WO2003009848A1 (enExample)
ZA (1) ZA200308991B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100834232B1 (ko) * 2004-01-30 2008-05-30 화이자 프로덕츠 인크. 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제
JP2007519701A (ja) 2004-01-30 2007-07-19 ファイザー・プロダクツ・インク 麻酔回復を改善するためのnk−1受容体拮抗剤
MXPA06012504A (es) * 2004-04-30 2006-12-15 Schering Corp Moduladores del receptor neuropeptido.
CN114403042A (zh) * 2021-12-13 2022-04-29 深圳先进技术研究院 一种大动物焦虑症动物模型

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
FR2677361A1 (fr) * 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE122006000066I2 (de) * 1991-05-31 2007-12-06 Pfizer Chinuclidinderivate
BR9206161A (pt) * 1991-06-20 1995-10-31 Pfizer Derivados fluoroalcoxibenzilamino de heterociclos contendo nitrogénio
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
EP0623344B1 (fr) * 1993-05-04 2000-07-26 Ceva Sante Animale Utilisation de la Sélégiline en médecine vetérinaire
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0719266A1 (en) * 1993-09-17 1996-07-03 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
US5854262A (en) * 1993-10-07 1998-12-29 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
PE45195A1 (es) * 1994-03-03 1996-01-17 Boehringer Ingelheim Kg Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
ATE279406T1 (de) * 1995-01-12 2004-10-15 Glaxo Group Ltd Piperidinderivate mit tachykinin-antagonistischer wirkung
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69710921T2 (de) * 1996-12-19 2002-09-19 Aventis Pharmaceuticals Inc., Bridgewater Heterocyclische substituierte pyrrolidinamid-derivate
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
JP4669095B2 (ja) * 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
CA2280309C (en) * 1999-08-13 2007-05-08 William Norton Milgram Use of adrafinil to treat behavioral problems in aged canines
CA2324813A1 (en) * 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety

Also Published As

Publication number Publication date
CZ200434A3 (cs) 2005-02-16
SK252004A3 (sk) 2005-03-04
PL367944A1 (en) 2005-03-07
US20030139443A1 (en) 2003-07-24
JP2005504029A (ja) 2005-02-10
CA2448722A1 (en) 2003-02-06
ZA200308991B (en) 2004-11-19
KR20040029375A (ko) 2004-04-06
EP1411946A1 (en) 2004-04-28
CN1529600A (zh) 2004-09-15
WO2003009848A1 (en) 2003-02-06
IL158990A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
CY1108336T1 (el) Θεραπεια νευρολογικων και νευροψυχολογικων διαταραχων
DE60324449D1 (de) Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
ATE423560T1 (de) Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
CY1108461T1 (el) Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζας
ATE438401T1 (de) 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
BRPI0409689A (pt) ligantes do receptor de canabinóides e sua utilização
ATE302194T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
ME00571A (en) Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
ATE424194T1 (de) Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
HUP0401154A2 (hu) NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására
DK1392348T3 (da) Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonister
MX2007005238A (es) Una composicion veterinaria transmucosal que comprende detomidina.
ATE282625T1 (de) Gaba-c-rezeptor-antagonisten zur stimulation des erinnerungsvermögens
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
DK1776016T3 (da) Fodre tilsætningsstoffer
BR0208241A (pt) Composto, composições farmacêutica métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção, ou demência de alzheimer, para aumentar a potência de um efeito terapêutico de um agente do cns, para determinar a presença ou ausência de receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, e, uso de um composto
CY1107062T1 (el) ΧΡΗΣΗ ΔΡΑΣΤΙΚΩΝ ΟΥΣΙΩΝ ΜΕ ΔΡΑΣΗ ΑΓΩΝΙΣΤΗ μ-ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΚΑΙ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΩΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΕΣΑ ΣΥΝΔΥΑΣΜΟΥ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ
DE60018186D1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen
ID29818A (id) Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial
EP1715863A4 (en) IMPROVEMENT OF AMPAKINE-INDUCED FACIALIZATION OF SYNAPTIC REACTIONS BY CHOLINESTERASE INHIBITORS
DK1357941T3 (da) Terapeutisk anvendelse af anti-MAG-antistof til behandling af iskæmisk slagtilfælde
PT1254120E (pt) Uso de antagonistas de endotelina de pirimidina em animais de companhia
SE9904863D0 (sv) New use
DE60313994D1 (de) Tierfutter mit ketoprofen-zusatz und seine verwendung bei der gleichzeitigen behandlung einer gruppe von tieren für vorgänge, die mit fieber, entzündung und/oder schmerzen einhergehen

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees